Project Grant K01AI202078
Award Date 7/1/26
Completion Date 6/30/29
Dollars Obligated $161K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charlottesville, VA 22904, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $236,660 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate IL-33-dependent and IL-33-independent pathways in allergic asthma. The project examines how IL-33 signaling drives type-2 inflammatory responses in allergic asthma and why blockade of IL-33 has produced mixed clinical trial results despite its position as an upstream therapeutic target. The...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $444,125 to the University of Virginia on February 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to decode immune responses during sequential rhinovirus infections. The recipient will conduct a comprehensive analysis of immune cells and anti-viral mediators in blood and nasal specimens collected during sequential homotypic and heterotypic...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $713,396 on August 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on the molecular mechanisms of protective lung resident memory T cells. The project examines how lung tissue-resident memory CD8+ T cells provide broad-spectrum protection against influenza infection, including heterologous protection against variant strains. The research focuses on a...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $773,388 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to decode the cellular networks governing respiratory mucosal IgA immunity. The research addresses mechanisms driving robust respiratory mucosal immunity, particularly IgA responses following infection or vaccination, with the goal of informing next-generation mucosal vaccine strategies against...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $795,313 on August 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on subcellular definition of accumulation in Escherichia coli as a strategy to address antimicrobial resistance. The research seeks to formulate foundational principles governing molecular characteristics that define cellular penetration in bacteria, similar to Lipinski's Rule of Five...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $242,250 on April 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate microbial drivers of oral vaccine failure in undernourished populations. The research addresses environmental enteric dysfunction, a subclinical intestinal malabsorption syndrome linked to growth stunting and undernutrition. Oral rotavirus vaccination shows significantly reduced efficacy in...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $668,128 on August 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop artificial intelligence and machine learning methods for hospital-acquired infection risk prediction, surveillance, and infection control. The recipient will design a multi-disciplinary approach combining deep learning, agent-based modeling, human factors, and systems science to address gaps...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded the University of Virginia $253,445 on August 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanistic insights into enteropathogen-mediated MUC3/4 signaling disruption and intestinal inflammation onset. The research uses human intestinal organoids to examine novel mechanisms triggering intestinal inflammation and mucosal...
- The National Institute of Allergy and Infectious Diseases awarded the University of Arizona $806,740 on August 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize the mechanisms by which natural environmental agents from traditional Amish farms protect the lungs against rhinovirus infection and associated asthma development in children. The research investigates how early-life exposure to cow barn environments and barn-derived substances present...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3.05 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Virginia on September 12, 2025, with a completion date of August 31, 2029. This research initiative investigates paired receptor signaling in natural killer (NK) cells to understand antiviral immunity and viral control mechanisms. The project employs advanced molecular...